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Abstract 
Background: Rare diseases are chronic and life-threatening disorders affecting < 1 person every 2,000. For most of 
them, clinical symptoms and signs can be observed at birth or childhood. Approximately 80% of all rare diseases have 
a genetic background and most of them are monogenic conditions. In addition, while the majority of these diseases 
is still incurable, early diagnosis and specific treatment can improve patients’ quality of life. Transplantation is among 
the therapeutic options and represents the definitive treatment for end-stage organ failure, both in children and 
adults. The aim of this paper was to analyze, in a large cohort of Italian patients, the main rare genetic diseases that led 
to organ transplantation, specifically pointing the attention on the pediatric cohort.
Results: To the purpose of our analysis, we considered heart, lung, liver and kidney transplants included in the Trans-
plant Registry (TR) of the Italian National Transplantation Center in the 2002–2019 timeframe. Overall, 49,404 recipi-
ents were enrolled in the cohort, 5.1% of whom in the pediatric age. For 40,909 (82.8%) transplant recipients, a disease 
diagnosis was available, of which 38,615 in the adult cohort, while 8,495 patients (17.2%) were undiagnosed. There 
were 128 disease categories, and of these, 117 were listed in the main rare disease databases. In the pediatric cohort, 
2,294 (5.6%) patients had a disease diagnosis: of the 2,126 (92.7%) patients affected by a rare disease, 1,402 (61.1%) 
presented with a monogenic condition. As expected, the frequencies of pathologies leading to organ failure were dif-
ferent between the pediatric and the adult cohort. Moreover, the pediatric group was characterized, compared to the 
adult one, by an overall better survival of the graft at ten years after transplant, with the only exception of lung trans-
plants. When comparing survival considering rare vs non-rare diseases or rare and monogenic vs rare non-monogenic 
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Background
Rare diseases are chronic and debilitating disorders 
affecting a small number of people compared to the 
general population, with small differences in definition. 
In the USA, a disease is considered to be rare when it 
affects < 200,000 people in the country, while in Europe 
the frequency is < 1 in 2,000 people (1, 2). In addition, 
there are geographical issues, as diseases that are gen-
erally rare can be frequent in a specific population. For 
example, the congenital nephrotic syndrome of the 
Finnish type is generally a rare disease, with the excep-
tion of Finland, where it occurs more frequently than in 
other parts of the world (3). Although each rare disease 
affects a small number of patients, globally considered 
they result in roughly 400 million patients.
Approximately 80% of all rare diseases are genetic in 
origin and most of them display a family distribution 
compatible with a monogenic origin (4, 5), even though 
in a proportion of disorders the causative gene remains 
elusive (5, 6). In this context, the recent evolution and 
broader application of sequencing technologies have 
revealed the genetic causes of novel rare disease and 
led to the identification of new variants responsible for 
previously defined disorders (7).
Rare diseases are often progressive conditions and 
for most of them clinical symptoms and signs can be 
observed at birth or childhood, being responsible for 
35% of deaths in the first year of life and a significant 
cause of pediatric hospital admissions (8–10). Moreo-
ver, in a considerable percentage of cases, they are 
severe multisystem disorders displaying a range of 
phenotypes with consequent diagnostic and patient 
management challenges. Notably, the great majority 
(95%) of the 7,000–8,000 estimated rare diseases still 
lack FDA/EMEA approved therapies (11), even though 
symptomatic treatment and medical care can improve 
patients’ quality of life and extend life expectancy.
Transplantation is one of the options and represents 
the definitive treatment for end-stage organ failure, 
both in children and adults. The advent of new immu-
nosuppressive drugs and the improvement of surgical 
techniques have contributed to its widespread diffu-
sion, which in turn has led to an expansion of medical 
indications and an increased organ need (12, 13).
This heightened demand, together with a non-pro-
portional raise in organs availability, impose the ethical 
need that “no organ can be used for futile transplants or 
burdened by a poor prognosis” (14, 15). In 2019, a total 
of 34,285 transplants were performed in Europe (21,235 
kidney; 7,900 liver; 2,269 heart; 2,136 lung; 710 pancreas 
and 35 small bowel), which is however a small fraction 
when compared to the number of waiting listed patients 
in the same period (109,739 patients in total: 79,513 kid-
ney; 16,007 liver; 6,940 heart; 4,883 lung; 2,313 pancreas 
and 83 small bowel) (16).
An open point in transplantation is the impact of rare 
diseases, specifically the ones with a genetic origin, since 
a significant percentage of end-stage organ failures are 
caused by monogenic pathologies (17, 18). Even though 
a wide variety of rare diseases benefit from solid organ 
transplantation, few reports address this topic from the 
genetic point of view.
The main aim of this paper is to analyze, in a large 
cohort of Italian patients, which are the main genetic dis-
eases that lead to organ transplantation. Specifically, we 
aimed to shed light on pediatric transplantation, evaluat-
ing which among these pathologies lead more frequently 
to transplantation, the frequencies of rare and monogenic 
diseases and the organs involved. Finally, we analyzed 
the transplant outcome comparing patients with rare 
diseases—distinguishing even the most frequent mono-




In the January 2002—December 2019 timeframe, the 
Transplant Registry (TR) of the National Transplantation 
Center database recorded 59,941 solid organ transplants, 
consecutively performed in Italy, of which 56,907 from 
cadaveric donors.
To the purpose of this study, due to low numbers, sin-
gle pancreas (n = 1,146) and small bowel (n = 55) trans-
plants were excluded from analysis, while re-transplanted 
patients were considered only once. Moreover, the cohort 
included recipients who underwent combined organ 
transplantation, both same organ (e.g., bi-pulmonary 
or bi-renal) and multi-organs (4,372 in total; Additional 
file  1: Table  1). Overall, our analysis, included kidney 
conditions, no differences were highlighted for kidney and lung transplants, while rare diseases had a better survival 
in liver as opposed to heart transplants.
Conclusions: This work represents the first national survey analyzing the main genetic causes and frequencies of rare 
and/or monogenic diseases leading to organ failure and requiring transplantation both in adults and children.
Keywords: Rare diseases, Monogenic diseases, Organ transplantation, Transplant outcome
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(n = 25,407), liver (n = 17,207), heart (n = 4,868), and lung 
(1,922) transplants, resulting in an enrolled cohort of 
49,404 recipients (Table 1). In 40,909 (82.8%) transplants, 
a definite diagnosis of disease leading to organ failure was 
available, of which 38,615 in the adult cohort and 2,294 
in the pediatric one, while 8,495 patients (17.2%) were 
present in the TR without a diagnosis. Transplants were 
performed in 47 Italian Transplant Centers, of which 34 
involved in pediatric activities (Additional file 1: Table 2).
We then focused the attention on the pediatric cohort, 
defined as patients who were less than 18  years old 
when enrolled in the waiting list, and included in the 
TR with a disease diagnosis (n = 2,294). The mean age 
at the time of enrollment in the TR was 7.15 years, IQR 
[1–13 years], with differences when considering the type 
of organ (heart: 7.84; liver: 4.06; lung: 13.04; kidney: 
9.86), while the mean age at the time of transplantation 
was 7.99 years, IQR [1–14].
To understand the impact of rare monogenic patholo-
gies in this cohort, we matched the diseases categories 
entered in the TR with those listed in the main rare 
diseases databases. Based on TR data entries, overall, 
there were 128 disease categories: 66 for kidney, 39 for 
liver, 14 for heart and 9 for lung (Table 1). Of them, 117 
were listed in the main rare disease databases. Within 
the pediatric cohort, 2,126 out of 2,294 (92.6%) pre-
sented with a rare disease (840 kidney; 920 liver; 273 
heart and 93 lung) of which 1,402 affected by a mono-
genic disease (411 kidney; 686 liver; 223 heart and 82 
lung; Table 1).
Overall, the median follow-up from the transplant 
date was similar for the organs considered in the study: 
6.73 years, IQR [2.48–10.57] for kidney; 5.39 years, IQR 
[1.23–8.87] for liver; 6.39  years, IQR [1.32–10.74] for 
heart; 3.6 years, IQR [0.39–5.62] for lung.
Transplants in the Italian pediatric and adult cohorts: state 
of the art
We then concentrated on patients with a clear diagno-
sis, looking at the distribution of transplants in the Ital-
ian cohort comparing the pediatric and adult groups, 
and taking in consideration i) transplanted organs, ii) 
main disease macro-categories that led to organ fail-
ure and iii) graft survival at 10  years after transplant. 
For the sake of clarity, this paragraph was divided in 
subparagraphs focused on the different transplanted 
organs.
Table 1 Transplanted organ category and main features of the cohort included in the study
Transplanted organ
Kidney Liver Heart Lung Total
N. of transplants 25,407 17,207 4,868 1,922 49,404
Without diagnosis of the original disease 5,967 334 1,611 583 8,495
With diagnosis 19,440 16,873 3,257 1,339 40,909
Adults 18,553 15,836 2,981 1,245 38,615
Pediatrics 887 1,037 276 94 2,294
N. of pediatric disease categories 66 39 14 9 128
N. of pediatric diseases included in the rare disease catalogs 61 35 13 8 117
N. of pediatric patients diagnosed with a rare disease 840 920 273 93 2,126
N. of pediatric patients diagnosed with a monogenic disease 411 686 223 82 1,402
Table 2 Heart transplant cohort and main disease categories leading to transplantation
Disease macro-category Pediatrics (n. 276) Adults (n. 2,981) Total (n. 3,257)
n. (%) n. (%) n. (%)
Cardiomyopathies 176 (63.8) 1,597 (53.6) 1,773 (54.4)
Congenital heart disease 84 (30.4) 82 (2.8) 166 (5.1)
Valve heart disease 5 (1.8) 161 (5.4) 166 (5.1)
Coronary disease 3 (1.1) 939 (31.5) 942 (28.9)
Primary lung hypertension 0 (0.0) 3 (0.1) 3 (0.1)
Other congenital pathologies 3 (1.1) 7 (0.2) 10 (0.3)
Other cardio-circulatory diseases 5 (1.8) 192 (6.4) 197 (6.0)
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Heart
For 3,257 heart transplanted patients (66.9% of all heart 
transplants) a diagnosis was recorded in the TR; of them 
276 were children (8.5%) and 2,981 adults (91.5%). While 
cardiomyopathies represented the first cause of disease 
both in children (63.8%) and adults (53.6%), coronary 
heart disease and valve heart disease were prevalent in 
adults (31.5% vs 1.1% and 5.4% vs 1.8%, respectively). On 
the other hand, children were significantly more affected 
by congenital heart disease than adults (30.4% vs 2.8%). 
It is also noteworthy that in the adult group, a significant 
proportion of patients were affected by other cardio-cir-
culatory diseases (5.8%; Table 2).
When looking at graft survival, children had a better 
outcome than adults (p < 0.001, Fig. 1a).
Lung
Of the 1,922 lung transplants, 1,339 (69.7%) had a 
detailed disease diagnosis. The analysis therefore 
focused on 1,245 adults (93%) and 94 pediatric cases 
(7%; Table 1). In children, in line with recent published 
data (19), the most frequent cause of organ failure was 
cystic fibrosis (79.8%), followed by primary pulmonary 
hypertension (7.4%), congenital disorders and other 
pneumopathies (4.3% each), which together accounted 
for 95.8% of cases. On the contrary, in adult patients, 
idiopathic pulmonary fibrosis was the most frequent 
cause of disease (35.9%), followed by cystic fibrosis 
(28.4%), emphysema/chronic obstructive pulmonary 
disease (18.4%) and other pneumopathies (11.6%). 
These 4 categories explained approximately 95% of 
cases (Table 3).
The success of lung transplantation was similar in 
pediatric and adult patients, with no significant differ-
ences at 10 years (Fig. 1b), even when excluding cystic 
fibrosis from the cohort (data not shown), in line with 
previously reported data (20).
Fig. 1 Overall graft survival of transplanted patients in the 2002–2019 timeframe. Kaplan–Meier curves comparing adult (purple line) vs. pediatric 
(green line) transplanted cohort. Heart (p < 0.001; 4248 adults vs 403 children; a); Lung (p = 0.700; 1445 adults vs 94 children; b); Liver (p < 0.001; 
14,215 adults vs 967 children; c) and Kidney (p < 0.001; 17,588 adults vs 817 children; d) 
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Liver
Out of the 17,207 liver recipients, 1,077 were per-
formed in children (6.3%) and 16,873 patients (98.1% of 
cases) were registered in the TR with a diagnosis. There 
were 462 different disease definitions, which could be 
grouped into 9 diagnostic macro-categories, as shown 
in Table 4. Specifically, in the pediatric cohort, the most 
represented diseases were atresia of the biliary tract 
(41.8%), other hepatopathies (17.3%), metabolic dis-
eases (12.2%), cholestatic cirrhosis (11.7%), and neo-
plasia (8%), accounting for 94% of all cases. On the 
contrary, in adults, the most frequent diagnoses were 
non-cholestatic cirrhosis (37.6%) and liver neoplasia 
(28.4%), followed by alcoholic cirrhosis (10.6%), chole-
static cirrhosis and cholestatic diseases (5.4%), other 
liver diseases (5.5%), accounting for 90% of all cases 
(Table 4).
When comparing the probability of graft success 
between the pediatric and adult cohort, the former pre-
sented an overall better survival than adults (p < 0.001; 
Fig. 1c).
Kidney
Lastly, we analysed kidney transplants with 25,407 
patients included in the TR. 19,440 recipients were reg-
istered with a disease diagnosis (76.5%), of which the 
great majority (95.4%) were adults with only 887 pedi-
atric patients (4.6%; Table  1). There were 568 differ-
ent disease definitions, which could be grouped into 13 
macro-categories (Table 5). In pediatric transplants, con-
genital familial nephro- and uropathies were the most 
represented pathologies (75.5% vs 2% in adults), fol-
lowed by glomerular (10%) and cystic (4.8%) nephropa-
thies. On the other hand, the most frequent pathologies 
in adult kidney transplants were glomerular nephropa-
thies (40.1%), followed by cystic nephropathies (18.8%), 
other renal disorders (11%), hypertensive nephrosclero-
sis (8.7%), diabetic nephropathy (7.6%) and tubular and 
interstitial nephropathies (7.1%), the latter 3 macro-cate-
gories being almost absent in the pediatric cohort.
Kaplan–Meier curves of the overall graft survival 
referred to kidney and comparing the pediatric and adult 
cohorts, showed that the former one was characterized 
by a better outcome (p < 0.001; Fig. 1d).
Table 3 Lung transplant cohort and main disease categories leading to transplantation
Disease macro-category Pediatrics (n. 94) Adults (n. 1,245) Total (n. 1,339)
n. (%) n. (%) n. (%)
Cystic fibrosis 75 (79.8) 354 (28.4) 429 (32.0)
Primary pulmonary hypertension 7 (7.4) 51 (4.1) 58 (4.3)
Other pneumopathies 6 (6.4) 148 (11.9) 154 (11.5)
Congenital disorders 4 (4.3) 1 (0.1) 5 (0.4)
Emphysema/Chronic obstructive pulmonary disease 1 (1.1) 229 (18.4) 230 (17.2)
Idiopathic pulmonary fibrosis 1 (1.1) 447 (35.9) 448 (33.5)
Congenital heart disease 0 (0.0) 4 (0.3) 4 (0.3)
Alpha-1 antitripsin deficiency 0 (0.0) 11 (0.9) 11 (0.8)
Table 4 Liver transplant cohort and main disease categories leading to transplantation
Disease macro-category Pediatrics (n. 1,037) Adults (n. 15,836) Total (n. 16,873)
n. (%) n. (%) n. (%)
Hepatopathies from atresia of the biliary tract 433 (41.8) 32 (0.2) 465 (2.8)
Metabolic diseases 126 (12.2) 350 (2.2) 476 (2.8)
Cholestatic cirrhosis and other cholestatic liver diseases 121 (11.7) 857 (5.4) 978 (5.8)
Neoplasia 83 (8.0) 4,505 (28.4) 4,588 (27.2)
Acute liver necrosis 44 (4.2) 404 (2.6) 448 (2.7)
Other non-cholestatic cirrhosis 43 (4.1) 5,950 (37.6) 5,993 (35.5)
HBV/HCV related cirrhosis 5 (0.5) 1,116 (7.0) 1,121 (6.6)
Alcoholic cirrhosis 0 (0.0) 1,686 (10.6) 1,686 (10.0)
Other hepatopathies 182 (17.5) 936 (5.9) 1,118 (6.6)
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Rare and monogenic diseases frequencies in pediatric 
transplanted patients and their impact on grafts survival
In the last section of the work, we focused selectively on 
the pediatric cohort of transplanted patients, included 
in the TR with a clear diagnosis, with the aim of defin-
ing the frequencies of rare and/or monogenic diseases 
that were causative of organ failure, ultimately requiring 
organ transplantation. For the former group of patholo-
gies, we firstly matched the main databases reporting 
these diseases to obtain a full list for each organ. Rare 
diseases are indicated with the Orphanet code. The diag-
noses included in the TR were then classified according 
to disease categories in rare and rare monogenic diseases. 
As a last inquiry, we compared graft survival in patients 
affected by i) rare vs non-rare diseases, ii) rare mono-
genic vs rare non-monogenic diseases and finally iii) con-
sidering the most represented disease macro-categories 
for each organ.
13 out of 14 diseases categories responsible for heart 
transplantation in children were included in the rare 
disease catalogues, accounting for almost all pediat-
ric patients with heart transplantation (273 out of 276, 
98.9%), with 223 patients (82%) diagnosed with a pathol-
ogy belonging to monogenic diseases. The only condi-
tion found in pediatric cases that is not considered a 
rare disease was dilated heart disease on ischemic basis 
(3 patients). However, it is not possible to exclude with 
certainty that even in these cases a rare/monogenic 
pathology was involved, possibly due to disorders of lipid 
metabolism. The most represented pathology was dilated 
cardiomyopathy (42.8% of cases), followed by congenital 
heart disease on a genetic basis (30.8%), hypertrophic 
cardiomyopathy (8.3%) and restrictive cardiomyopathy 
(7.6%). Alone, these 4 disease categories represented 89% 
of pediatric transplants (Table 6).
If we distinguish pediatric transplants according to 
whether they have been performed because of a rare vs 
a non-rare disease, we noted that the probability of suc-
cess was significantly better for transplants performed in 
children without rare diseases (p < 0.05; Fig. 2a). On the 
contrary, transplants performed because of a monogenic 
disease presented a significantly better chance of success 
(p < 0.05; Fig. 2b). Finally, when considering the outcome 
of the transplant taking into account the 2 most repre-
sented groups of cardiac diseases, congenital pathologies 
and cardiomyopathies, no significant differences were 
highlighted between them, even though they showed 
a significant better profile compared to other cardiac 
pathologies (p < 0.01; Fig. 2c).
When analysing in detail the 9 different definitions of 
disease found in lung transplanted patients and classify-
ing them according to rare diseases, we noted that almost 
all patients (98.9%) were affected by rare diseases, of 
whom 86% of monogenic origin. Cystic fibrosis was the 
leading cause of lung failure, affecting 80.6% of the whole 
cohort. The second most frequent diagnosis was repre-
sented by pulmonary arterial hypertension, a rare disease 
of non-monogenic nature, counting 7.5% of patients.
(Table 7).
Since more than 50% of pediatric transplants were per-
formed in recipients with cystic fibrosis, which is a rare 
and monogenic disease, further evaluations in relation to 
the outcome of pediatric transplants were strongly influ-
enced by this single category. Moreover, due to an almost 
Table 5 Kidney transplant cohort and main disease categories leading to transplantation
Disease macro-category Pediatrics (n. 887) Adults (n. 18,553) Total (n. 19,440)
n. (%) n. (%) n. (%)
Congenital familial rare and metabolic based nephro- 
and uro-pathies
670 (75.5) 378 (2.0) 721 (3.7)
Glomerular nephropathies 89 (10.0) 7,438 (40.1) 7,527 (38.7)
Cystic nephropathies 43 (4.8) 3,493 (18.8) 3,536 (18.2)
Acute renal insufficiency 13 (1.5) 43 (0.2) 56 (0.3)
Other familial nephropathies 12 (1.4) 227 (1.2) 239 (1.2)
Different nephro-vasculopathic and nephrosclerosis 
syndromes
7 (0.8) 389 (2.1) 396 (2.0)
Kidney neoplasia 2 (0.2) 53 (0.3) 55 (0.3)
Hypertensive nephrosclerosis 1 (0.2) 1,610 (8.7) 1,611 (8.3)
Tubular and interstitial nephropathies 0 (0.0) 1,326 (7.1) 1,326 (6.8)
Diabetic nephropathy 0 (0.0) 1,409 (7.6) 1,409 (7.2)
Non-cholestatic cirrhosis 0 (0.0) 2 (0.0) 2 (0.0)
Other hepatopathies 3 (0.3) 1 (0.0) 4 (0.0)
Other kidney disorders 47 (5.3) 2,184 (11.8) 2,558 (13.2)
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complete overlap between rare and monogenic diseases 
also in the remaining categories, we did not perform sur-
vival analyses. And indeed, the overall survival between 
cystic fibrosis diagnosed patients and all the other disease 
categories showed no differences (p = 0.653; Fig.  3), in 
line with previously reported data (19).
Regarding liver pediatric transplants, there were 39 
different definitions of diseases available in the TR, with 
the great majority included in the catalogues of rare dis-
eases (36 out of 39 disease categories, accounting for 90% 
of patients) and 17 out of 39 being of monogenic origin, 
including almost 71% of patients. Analyzing the distribu-
tion of these diagnoses, it was noted that the most fre-
quent were congenital biliary disease/extrahepatic biliary 
atresia (41.1% of patients), cholestatic diseases (11.5%), 
metabolic diseases, including cystic fibrosis and primary 
hyperoxaluria (9.8%), Alagille syndrome (4.5%), and Wil-
son disease (1.7%), which all together constituted approx-
imately 70% of all cases (Table 8).The distribution in this 
cohort is slightly a bit different from the ones previously 
reported by Fagiuoli and colleagues, where the dominant 
phenotype was represented by Alagille syndrome (21).
Pointing the attention on the graft survival of pediatric 
liver transplants, those performed in patients with rare 
diseases showed a significantly better outcome compared 
to patients with common diseases (p < 0.005; Fig. 4a). On 
the contrary, no differences were noted when dividing 
them based on the presence or absence of a monogenic 
disease (p = 0.87; Fig.  4b). When plotting graft survival 
according to the main diagnostic categories, globally 
considered, no statistically significant differences were 
highlighted (p = 0.11). However, a trend towards a bet-
ter outcome could be noted for metabolic diseases, bil-
iary atresia, and cholestatic diseases. On the contrary, 
transplants performed because of neoplasia and cirrhosis 
showed a worse overall survival (Fig. 4c).
Lastly, we looked at kidney transplants in the pediatric 
cohort. The list contained 66 different disease categories, 
most of which (n = 62) included in the catalogues of rare 
diseases. Overall, 94.7% of transplanted patients had a 
diagnosis of rare disease and half of these ones (46.3%) 
had a monogenic origin. The most represented diseases 
were renal or urinary tract malformation (36.9%), fol-
lowed by focal segmental glomerulosclerosis (8.1%), 
nephronophthisis (8%), autosomal recessive polycystic 
kidney disease (4.8%), glomerulonephritis (4.3%), con-
genital nephrotic syndrome Finnish type (3.8%), Alport 
syndrome (3%) and hemolytic uremic syndrome (2.9%). 
It is worthy to note that monogenic diseases might be 
underestimated, as monogenic forms of renal or urinary 
tract malformation and glomerulonephritis are known 
(Table 9).
In pediatric kidney transplants and similar to what 
observed for lung transplants, no significant differences 
were highlighted when comparing rare vs common dis-
eases (p = 0.36; Fig. 5a) or when considering monogenic 
vs non-monogenic diseases (p = 0.33; Fig. 5b) at ten years 
after transplant. However, when plotting overall graft 
survival taking in consideration the most representative 
disease macro-categories, some significant differences 
Table 6 Diagnostic categories in heart transplanted pediatric cohort and distribution between rare and monogenic diseases
Tx: transplants;
§ : included in the NORD database ( https:// rared iseas es. org/ rare- disea ses/ myoca rditis/)
Diagnosis ORPHA code Tx (n. 276) Rare diseases (n. 273) Monogenic diseases (n. 223)
n. (% respect to total Tx) n. (% respect to rare diseases)
Complication following organ transplant 306,644 1 1 (0.4)
Dilated cardiomyopathy 217,604 118 118 (42.8) 113 (41.4)
Dilated cardiomyopathy on ischemic basis 3
Ebstein malformation 1880 1 1 (0.4) 1 (0.4)
Familial isolated arrhythmogenic dysplasia of 
the right ventricle
217,656 1 1 (0.4) 1 (0.4)
Genetic heart disease 271,853 85 85 (30.8) 84 (31.1)
Hypertrophic cardiomyopathy 217,569 23 23 (8.3)
Hypoplastic left heart 2248 2 2 (0.7) 2 (0.7)
Myocarditis § 9 9 (3.3)
Radiation-induced pathology 521,132 5 5 (1.8)
Restrictive cardiomyopathy 217,632 21 21 (7.6) 21 (7.6)
Shone Complex 99,063 1 1 (0.4) 1 (0.4)
Severe aortic insufficiency 99,094 1 1 (0.4)
Valvular heart disease 228,410 5 5 (1.8)
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appeared, with glomerular and congenital nephropathies 
showing the best outcome as opposed to renal and uri-
nary tract abnormalities and focal segmental glomerulo-
sclerosis (p < 0.01; Fig. 5c).
Discussion
An ample body of literature comes out when surfing 
PubMed using “transplantation” or “organ transplants” 
as search keywords. Different aspects are addressed and 
discussed, mainly referring to clinical and surgical topics, 
as well as to immunological issues. In the last year, even 
the impact of COVID-19 has represented a “hot topic” in 
transplantation (22, 23). In this paper, solid organ trans-
plants are addressed and investigated from a genetic per-
spective, which is a relatively unexplored field (17, 18, 
24), thus strengthening the novelty of this work. We car-
ried out a national survey, based on data included in the 
Italian Transplant Registry (TR), by focusing on disease 
causes that lead to organ failure thus finally requiring 
transplants. Specifically, we reported the Italian “state of 
the art”, considering both the adult and pediatric cohorts, 
with the aim of comparing these two subsets of patients, 
highlighting the percentage of undiagnosed patients 
included in the TR, and describing the frequency and dis-
tribution of rare and monogenic diseases in transplants 
recipients. Several points of discussion can be raised 
from this analysis.
The first observation that comes to light concerns the 
percentage of patients included in the TR without a dis-
ease diagnosis. Considering all transplants, a diagno-
sis is recorded in 40,909 (82.8%) resulting in a 17.8% of 
transplanted patients who remain undiagnosed, in line 
with previous data (25–27). When dividing by organs, 
heart and lung transplants present with the higher per-
centage of undiagnosed patients (n = 1,611, 33.1% and 
n = 583, 30.3%, respectively), followed by kidney trans-
plants (n = 5,967, 23.5%), while only a minority of liver 
transplanted patients were without a diagnosis (n = 334, 
1.9%). A possible explanation for the higher percentage of 
diagnosed patients in TR for liver transplants compared 
to the other organs may rely on the structure of the TR, 
allowing for liver, and only for this organ, three different 
levels of diagnostic information to be recorded.
The second observation regards the quote of diagnosed 
pediatric transplants (2,294 patients in total, 5.6% of all 
diagnosed transplanted patients). Depending on the 
organ considered, the percentage of diagnosed patients 
varies, being the highest for heart (8.5%), followed by 
liver (6.1%) and lung (7.0%). On the contrary, kidney 
presented the lower quote of diagnosed patients (4.5%). 
It is noteworthy that the frequencies and distribution 
of pathologies leading to organ transplants are different 
between the adult and pediatric cohorts, especially when 
Fig. 2 Survival of heart transplanted patients in the 2002–2019 
timeframe. a Kaplan–Meier curves comparing patients affected by 
rare diseases (green line; n = 240) vs. patients affected by non-rare 
diseases (red line; n = 163) [p < 0.05]. b Kaplan–Meier curves 
comparing patients affected by monogenic diseases (green line; 
n = 196) vs. patients affected by rare non-monogenic diseases (red 
line; n = 44) [p < 0.05]. c Kaplan–Meier curves comparing patients 
affected by cardiomyopathies (Card_myop; blu line; n = 158) vs. 
congenital pathologies (Cong_Path; red line; n = 74) vs. other 
pathologies (Other; green line; n = 8) [p < 0.01]
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analysing kidney and liver transplants. Moreover, the 
quote of pediatric kidney transplants is lower compared 
to the other organs, when taking in consideration the 
overall number of transplants for each organ. This lower 
percentage is probably linked to different factors: firstly, 
kidney diseases may take a longer period of time to lead 
to organ failure. In line with this hypothesis, the mean 
age of enrollment in the TR is higher for kidney patients 
(9.86  years) compared to heart and liver ones (7.84 and 
4.06  years, respectively). Secondly, kidney transplant 
does not represent a lifesaving treatment as other options 
can temporarily supply to organ dysfunction.
The third point of discussion is centred on the dis-
ease categories within the pediatric cohort. Overall, we 
listed 128 different diseases, with kidney transplants 
contributing the most to this catalogue (51.5%), fol-
lowed by liver (30.5%), heart (10.9%) and lung (7.0%). 
However, it must be noted that the number of pediatric 
patients with diagnosis who underwent either a heart 
or lung transplant is relatively small. Interestingly, out 
of 128 disease categories identified, 117 are included 
in the main catalogues of rare diseases, meaning that 
92.7% of the pediatric cohort is affected by this type 
of diseases. This proportion varies slightly depend-
ing on the organ involved, being higher for thoracic 
organ transplants (98.9%) compared to abdominal 
ones (94.7% for kidney and 88.7% for liver). An inter-
esting result that has been highlighted by this survey is 
that a considerable percentage (65.9%) of the pediatric 
patients presenting with a rare disease is affected by 
a monogenic condition. As expected, lung, heart and 
liver transplants presented the higher quote of mono-
genic diseases (88%, 81.7% and 74.6%, respectively) 
at variance with kidney transplants, where < 50% of 
patients are affected by a disease of monogenic origin. 
This significant difference can be explained by the fact 
that within kidney, some categories of rare diseases 
may include a quote of monogenic pathologies (e.g., 
CAKUT, glomerulonephritis) thus leading to an under-
estimation of the real percentage. The distribution of 
affected patients seems to be independent of the sex 
in heart and liver transplants, while a clear association 
was present for lung and kidney ones. In the first case, 
there was a prevalence (63.8%) of female patients likely 
reflecting the fact that the great majority of the cohort 
was affected by cystic fibrosis. Several papers in litera-
ture suggest that a sex dichotomy exists for this disease, 
despite improved therapies, with female patients expe-
riencing a slightly worse prognosis, both in terms of 
mortality and susceptibility to chronic infections (28–
31). On the contrary, for kidney transplants, there was 
a prevalence of male subjects (61.8%). In part, these 
data can be explained by the fact that some diseases are 
characterized by an X-linked mode of inheritance (e.g., 
Alport syndrome) thus affecting male subjects. Beside 
the genetic aspect, these data are in line with evidence 
Table 7 Diagnostic categories in lung transplanted pediatric cohort and distribution between rare and monogenic diseases
Tx: transplants
Diagnosis ORPHA code Tx (n. 94) Rare diseases (n. 93) Monogenic diseases (n. 82)
n. (% respect to total Tx) n. (% respect to rare diseases)
Bronchiolitis obliterans 1303 2 2 (2.1)
Chronic obstructive pulmonary disease 1
Cystic fibrosis 586 75 75 (80.6) 75 (80.6)
Eisenmenger syndrome 97,214 4 4 (4.3) 4 (4.3)
Idiopathic pulmonary fibrosis 2032 1 1 (1.1) 1 (1.1)
Interstitial lung disease due to ABCA3 deficiency 440,402 1 1 (1.1) 1 (1.1)
Langerhans cell histiocytosis 389 1 1 (1.1) 1 (1.1)
Pulmonary arterial hypertension 182,090 7 7 (7.5)
Rejection/Complication after organ transplantation 306,644 2 2 (2.1)
Fig. 3 Survival of lung transplanted patients in the 2002–2019 
timeframe. Kaplan–Meier curves comparing pediatric patients 
affected by cystic fibrosis (blue line; n = 56) vs. pediatric patients 
affected by other pathologies (red line; n = 37) [p = 0.653]
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reported in literature showing that worldwide there is 
a milder male predominance among kidney transplant 
patients (32, 33).
When considering the graft survival, as expected (34), a 
clear statistically significant difference can be highlighted 
comparing the pediatric and adult cohorts, with the for-
mer group showing the best survival at ten years after 
transplants. The only exception, but in line with reported 
data (20, 35), is represented by lung, probably in part as a 
consequence of the over-representation of cystic fibrosis 
Table 8 Diagnostic categories in liver transplanted pediatric cohort and distribution between rare and monogenic diseases
Tx: transplants; GVHD: graft-versus-host disease; # several ORPHA codes
Diagnosis ORPHA code Tx (n. 1,037) Rare diseases (n. 904) Monogenic diseases (n. 689)
n. (% respect to total Tx) n. (% respect to rare diseases)
Acute liver failure—Fulminant or subfulminant 
hepatic failure
53
Alagille syndrome 52 47 47 (4.5) 47 (5.2)
Alpha-1 antitrypsin deficiency 60 11 11 (1.1) 11 (1.2)
Angiosarcoma (neoplasia) 263,413 1 1 (0.1)
Budd-Chiari syndrome 131 5 5 (0.5) 5 (0.5)
Caroli disease 53,035 6 6 (0.6)
Cholestatic disease—Primary biliary cirrhosis 186 17 17 (1.6)
Cholestatic disease—Primary sclerosing cholangitis 171 42 42 (4.1)
Cholestatic disease—Other 27
Cholestatic disease—Secondary biliary cirrhosis 447,774 29 29 (2.9)
Cirrhosis—Autoimmune 779 8 8 (0.8)
Cirrhosis—Other 10
Cirrhosis—Virus related 11
Congenital biliary disease—Extrahepatic biliary 
atresia
498,345 426 426 (41.1) 426 (47.1)
Crigler-Najjar syndrome type 1 79,234 4 4 (0.4) 4 (0.4)
Cryptogenic cirrhosis 24
Epithelioid hemangioendothelioma (neoplasia) 157,791 3 3 (0.3)
Familial hypercholesterolemia 391,665 1 1 (0.1)
Glycogen storage disease 79,201 6 6 (0.6) 6 (0.6)
GVHD 99,921 3 3 (0.3)
Hemochromatosis 220,489 5 5 (0.5) 5 (0.5)
Hepatic trauma 1
Hepatoblastoma (neoplasia) 449 55 55 (5.3)
Hepatocellular (neoplasia) 88,673 19 19 (1.8)
Hepatocellular carcinoma—Fibrolamellar (neoplasia) 401,920 2 2 (0.2)
Isolated Congenital hepatic fibrosis 485,426 19 19 (1.8) 19 (2.1)
Langherans cell histiocytosis 389 3 3 (0.3)
Metabolic disease—Cystic fibrosis 586 17 17 (1.6) 17 (1.9)
Metabolic disease—Others 91,088 49 49 (4.7) 49 (5.4)
Metabolic disease—Primary hyperoxaluria 416 25 25 (2.4) 25 (2.8)
Metabolic disease—Tyrosinemia 882/28378/ 68,723 11 11 (1.1) 11 (1.2)
Methylmalonic acidemia with homocystinuria, type 
cblD
79,283 3 3 (0.3) 3 (0.3)
Neonatal intrahepatic cholestasis caused by citrin 
deficiency
247,598 1 1 (0.1) 1 (0.1)
Other neoplasia 7
Other rare liver diseases # 26 26 (2.5)
Polycystic liver disease 2924 6 6 (0.6) 6 (0.6)
Progressive familial intrahepatic cholestasis 172 36 36 (3.5) 36 (4.0)
Wilson disease 905 18 18 (1.7) 18 (2.0)
Page 11 of 17Vaisitti et al. Orphanet J Rare Dis          (2021) 16:374  
Fig. 4 Survival of liver transplanted patients in the 2002–2019 
timeframe. a Kaplan–Meier curves comparing pediatric patients 
affected by rare diseases (green line; n = 900) vs. pediatric patients 
affected by non-rare diseases (red line; n = 67) [p < 0.005]. b Kaplan–
Meier curves comparing pediatric patients affected by monogenic 
diseases (green line; n = 227) vs. pediatric patients affected by rare 
non-monogenic diseases (red line; n = 673) [p = 0.876]. d Kaplan–
Meier curves comparing pediatric patients affected by rare diseases 
stratified on the basis of their diagnosis [p = 0.11]: biliary atresia (Bil_
atr; blue line; n = 420); cholestasis (Choles; light green line; n = 116); 
metabolic diseases (Metab_dis; grey line; n = 92); Cholangitis 
(Cholang; green line; n = 40); cirrhosis (Cirrh; yellow line; n = 73); 
neoplasia (Neopl; red line; n = 86); other diseases (Other; purple line; 
n = 73)
Fig. 5 Survival of kidney transplanted patients in the 2002–2019 
timeframe. a Kaplan–Meier curves comparing pediatric patients 
affected by rare diseases (green line; n = 758) vs. pediatric patients 
affected by non-rare diseases (red line; n = 59) [p = 0.364]. b Kaplan–
Meier curves comparing pediatric patients affected by monogenic 
diseases (green line; n = 367) vs. pediatric patients affected by 
rare non-monogenic diseases (red line; n = 391) [p = 0.331]. d 
Kaplan–Meier curves comparing pediatric patients affected by rare 
diseases stratified on the basis of their diagnosis [p < 0.01]: congenital 
nephrosis (Cong_Nephr; blue line; n = 59); glomerular nephrosis 
(Glom_nephr; green line; n = 84); focal segmental glomerulosclerosis 
(Foc_seg_glom; red line; n = 95); nephronophtisis (Nephronoph; 
yellow line; n = 65); renal and urinary tract disorders (Ren_urin_tract; 
pink line; n = 326); other diseases (Other; purple line; n = 129)
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Table 9 Diagnostic categories in kidney transplanted pediatric cohort and distribution between rare and monogenic diseases
Diagnosis ORPHA code Tx (n. 887) Rare diseases (n. 837) Monogenic diseases (n. 413)
n. (% in respect to total Tx) n. (% respect to rare diseases)
Alport syndrome 63 27 27 (3.0) 27 (3.3)
Autosomal dominant tubulointerstitial kidney disease 34,149 3 3 (0.3) 3 (0.4)
Autosomal dominant tubulointerstitial kidney disease 
due to HNF1B
93,111 1 1 (0.1) 1 (0.1)
Autosomal dominant tubulointerstitial kidney disease 
due to UMOD mutation
88,950 1 1 (0.1) 1 (0.1)
Autosomal recessive polycystic kidney disease 731 43 43 (4.8) 43 (5.2)
Bardet-Biedl syndrome 110 4 4 (0.5) 4 (0.5)
Branchiootorenal syndrome 107 5 5 (0.6) 5 (0.6)
Caroli Disease 53,035 1 1 (0.1) 1 (0.1)
CHARGE syndrome 138 1 1 (0.1) 1 (0.1)
Congenital nephrotic syndrome 97,556 2 2 (0.2) 1 (0.1)
Congenital nephrotic syndrome type 4 656 6 6 (0.7) 6 (0.7)
Congenital nephrotic syndrome Finnish type 839 34 34 (3.8) 34 (4.1)
Congenital nephrotic syndrome type 2 656 17 17 (1.9) 17 (2.1)
Congenital nephrotic syndrome type 3 656 2 2 (0.2) 2 (0.2)
Cranioectodermal dysplasia 1515 1 1 (0.1) 1 (0.1)
Cystinosis 213 16 16 (1.8) 16 (1.9)
Dense deposit disease 93,571 1 1 (0.1)
Denys-Drash syndrome 220 6 6 (0.7) 6 (0.7)
Ellis-Van Creveld syndrome 289 1 1 (0.1) 1 (0.1)
Fabry disease 324 1 1 (0.1) 1 (0.1)
Familial vesicoureteral reflux 289,365 12 12 (1.4) 12 (1.4)
Fanconi syndrome 3337 1 1 (0.1) 1 (0.1)
Fechtner syndrome 1984 1 1 (0.1) 1 (0.1)
Focal segmental glomerulosclerosis 656 72 72 (8.1) 72 (8.7)
Frasier syndrome 347 2 2 (0.2) 2 (0.2)
Glomerulonephritis 93,559 38 38 (4.3)
Goodpasture disease 375 1 1 (0.1)
Granulomatosis with polyangiitis 900 1 1 (0.1) 1 (0.1)
Hemolytic uremic syndrome 544,458 26 26 (2.9) 26 (3.1)




63,261 1 1 (0.1) 1 (0.1)
Hypertensive nephrosclerosis 1
Hypoplastic kidneys 93,101 10 10 (1.1)
IgA nephropathy 761 8 8 (0.9)
Jeune syndrome 474 1 1 (0.1) 1 (0.1)
Joubert syndrome with oculorenal anomalies 2318 13 13 (1.5) 13 (1.6)
Leopard syndrome 500 1 1 (0.1) 1 (0.1)
Lowe oculocerebrorenal syndrome 534 2 2 (0.2) 2 (0.2)
Lupus nephritis 300,345 8 8 (0.9)
Megaureter syndrome with oculorenal anomalies 238,637 1 1 (0.1)
Membranous nephropathy 97,560 3 3 (0.3)
Methylmalonic acidemia 293,355 2 2 (0.2) 2 (0.2)
Microscopic polyangiitis 727 3 3 (0.3)
Mitochondrial DNA-associated Leigh syndrome 255,210 2 2 (0.2) 2 (0.2)
Nail-patella syndrome 2614 1 1 (0.1) 1 (0.1)
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both in children and adults. Within the pediatric cohort, 
a diagnosis of rare or monogenic disease is not by itself 
sufficient to predict graft survival probability. Indeed, a 
clear and unique trend was not evident by this analysis.
Overall, this survey has drawn attention on the sig-
nificant proportion of patients included in a waiting list 
or already transplanted who lack a disease diagnosis at 
the time of transplant (25–27). Moreover, a prominent 
quote of patients requiring organ transplantation are 
affected by rare and monogenic diseases (17, 18). These 
data open the discussion on the possibility to improve 
the diagnostic power by introducing genetic testing as 
part of the clinical flow before organ transplants, at least 
for some patient categories (36–39). The availability of 
sequencing platforms, the possibility to design selective 
gene panels for the analysis as well as the reduced costs 
of genetic tests may be in favour of this hypothesis, while 
avoiding doubtful exams and diagnosis. Having the cor-
rect diagnosis of the original disease that leads to organ 
insufficiency is relevant for many reasons, including i) 
the identification of the best therapeutic window to per-
form transplantation, ii) prevention of post-transplant 
complications that can be related to the original disease, 
iii) adoption of specific therapeutic regimens. This issue 
becomes even more relevant for rare and monogenic 
diseases where the genetic testing is crucial for a univocal 
diagnosis.
A further point to be stressed is that, at least for a 
small proportion of these patients, novel therapeutic 
approaches may represent a viable alternative to trans-
plantation. While this is currently available mostly in the 
context of clinical trials, it is conceivable that in the near 
future targeted treatments, such as gene therapy/editing 
and stem cell-based therapies may become available for 
an increasingly higher number of rare diseases (40–42).
Lastly, a final consideration regards the economic 
impact of transplants as a treatment strategy compared 
to conventional treatments. At least in Western coun-
tries, it is well known that transplantation is cost-effec-
tive compared to other options (43, 44). As an example, 
for kidney, transplantation is the best choice compared 
to dialysis, with an initial cost of approximately 45,000 
Euros that drops-off to 8,000 Euros starting from the sec-
ond year after transplantation.
Conclusions
This work was designed to provide an updated snapshot 
of organ transplants in Italy, considered from a genetic 
perspective. We went through the Italian Transplant 
Table 9 (continued)
Diagnosis ORPHA code Tx (n. 887) Rare diseases (n. 837) Monogenic diseases (n. 413)
n. (% in respect to total Tx) n. (% respect to rare diseases)
Neonatal cortical necrosis 13
Nephronophthisis 655 71 71 (8.0) 71 (8.6)
Nephropathy due to chemotherapy 1
Neurogenicbladder 84,085 2 2 (0.2)
Other nephropathy 31
Primary hyperoxaluria type 1 93,598 14 14 (1.6) 14 (1.7)
Primary hyperoxaluria type 2 93,599 1 1 (0.1) 1 (0.1)
Prune belly syndrome 2970 9 9 (1.0) 9 (1.1)
Renal agenesis 411,709 7 7 (0.8)
Renal coloboma syndrome 1475 3 3 (0.3) 3 (0.4)
Renal or urinary tract malformation 93,545 327 327 (36.9)
Renal-hepatic-pancreatic dysplasia-Dandy-Walker cysts 
syndrome
3032 1 1 (0.1) 1 (0.1)
Schimke immune-osseous dysplasia 1830 1 1 (0.1) 1 (0.1)
Sirenomelia 3169 1 1 (0.1) 1 (0.1)
Split hand urinary anomalies spina bifida (Czeizel-Losonci 
syndrome)
2437 4 4 (0.5)
Townes-Brocks syndrome 857 1 1 (0.1) 1 (0.1)
Trauma 1
VACTERL/VACTER association 887 2 2 (0.2) 2 (0.2)
Vasculitis 52,759 7 7 (0.8)
Wilms tumor 654 2 2 (0.2)
Tx: transplants
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Registry, considering both the adult and pediatric 
cohorts, focusing on disease diagnoses that lead to organ 
failure finally requiring transplants (Fig. 6). Remarkably, 
in 1 patient out of 5, transplantation was performed in 
patients lacking a diagnosis. Within the diagnosed sub-
set, the great majority of the pediatric patients presented 
with rare genetic diseases, most of them being affected by 
monogenic pathologies (Fig. 7).
The results of this work represent, to our knowledge, 
the first national survey on genetic diseases leading to 
organ transplants, being a novelty in the field. Moreover, 
they represent a starting point for future considerations 
on the relevance of disease diagnosis for patient man-
agement, taking into account also the increasing spread 




The Transplant Registry (TR) is entrusted to the Trans-
plant Information System (TIS), which is an infrastruc-
ture for the management of data related to the activity of 
the National Transplant Network, established and regu-
lated by Italian Laws (no. 91/99 and Decree of the Minis-
try of Health n. 130 of 20 August 2019).
Clinical data and rare and monogenic disease diagnosis
Several data are collected by the TR, including patients’ 
demographic and clinical information, survival after 
transplant, and indication of the disease that caused end-
stage organ failure. To this purpose, a specific in series 
classification is used for each organ to define macro- and 
sub-categories of pathologies, the latter used to provide 
more detailed features of the diagnosis.
To identify rare and monogenic diseases in our cohort, 
a list of these pathologies was generated, matching 
entries from the National Organization for Rare Disor-
ders (NORD; https:// rared iseas es. org/), Orphanet data-
base (https:// www. orpha. net/), the Genetic and Rare 
diseases information center (NIH-GARD, https:// rared 
iseas es. info. nih. gov/) and Online Mendelian Inheritance 
in Man catalog (OMIM, https:// www. omim. org/). In 
the case of the kidney, the available diagnosis in the TR 
did not allow for an unambiguous classification, and the 
pediatric kidney transplant centers were asked to fill in 
a specific form in order to identify the diagnosis of the 
disease in a more precise manner, allowing for rare and 
monogenic disease classification.
Statistical analyses
The Kaplan–Meier method was used to analyze over-
all graft survival (death non censored graft survival). 
These analyses were carried out considering transplant 
recipients i) with a follow up and ii) that underwent a 
first transplant. The corresponding number of patients 
considered are indicated in the figure legends. The log 
rank test was used to evaluate the statistical significance. 
For the age of registration in the transplant list and the 
age at transplant for the pediatric cohort, values were 
expressed as median (interquartile range) unless oth-
erwise specified. The Shapiro–Wilk normality test was 
used to evaluate normality distribution for continuous 
or ordinal dependent variable. Kruskal–Wallis test was 
used to assess for significant differences on a continuous 
Fig. 6 Sankey diagram showing the analytical flow adopted in the study. The diagram showed the different parameters that were taking into 
account in the present analyses: transplanted patients registered in the transplanted register (TR) in the 2002–2019 timeframe, cohort selection 
and inclusion/exclusion criteria, classification on the basis of presence/absence of a diagnosis indicated in the TR, analysis of the pediatric cohort 
based on a diagnosis of rare and/or monogenic diseases. Single pancreas and bowel transplants were excluded from the analysis, as well as 
re-transplanted patients
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dependent variable. P values < 0.05 were considered sta-
tistically significant. All data were analyzed using STATA 
(v 16.1 Copyright 1985–2019 StataCorp LP 4905 Lake-
way Drive College Station, Texas 77,845 USA).
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